VB-111

Gene therapy for ovarian cancer fails PhIII study — sinking VBL Therapeutics' shares
Endpoints
Wed, 07/20/22 - 09:33 am
VBL Therapeutics
gene therapy
ovarian cancer
VB-111
ofra-vec
VBL’s ovarian cancer drug comes though interim phase 3 review
Fierce Biotech
Thu, 08/13/20 - 09:42 am
VBL Therapeutics
clinical trials
VB-111
ovarian cancer
Failure in pivotal PhIII brain cancer trial drags Israel’s VBL Therapeutics down
Endpoints
Thu, 03/8/18 - 09:39 am
clinical trials
VBL Therapeutics
VB-111
Roche
Avastin
glioblastoma
6 Key Cancer Winners From ASCO Presentations
24/7 Wall St
Mon, 06/1/15 - 10:06 am
ASCO
Immunogen
mirevtuximab soravtansine
ONT-380
Oncothyreon
cabozantinib
Exelixis
VB-111
Vascular Biogenics
Immunomedics
sacituzumab govitecan
pacritinib
CTI BioPharma